Our mission
Dedicated to pioneering universal solutions for critical infectious diseases such as HCV, HIV, Influenza A, and JC virus.
R&D Activity
Harnessing the power of human monoclonal antibody cloning as the cornerstone for pioneering vaccine breakthroughs.
Commercial Activity
Empowering businesses with tailored recombinant proteins and customized antibodies to fuel innovation and growth.
Who we are
We are a private Italian
R&D biotech company
Every breakthrough at Pomona Ricerca is driven by our commitment to improving patient outcomes. We strive to enhance the quality of life for individuals by delivering effective and safe immunotherapeutic solutions. At the heart of Pomona Ricerca's vision lies a fervent dedication to advancing research in monoclonal antibodies to prevention and treatment of infectious diseases.
POMONA RICERCA
Our strategy
Pomona Ricerca provides indispensable services in the critical pre-clinical characterization stage of drug development.
The business model of Pomona Ricerca operates on three fronts:
- designing and developing new monoclonal antibodies, followed by out-licensing the mAbs at the pre-clinical characterization stage
- developing of antibody-based vaccines
- providing proteins and services for the characterization of new monoclonal antibodies
Our comprehensive approach, blending consolidated scientific expertise with cutting-edge technologies, positions us as an attractive partner for biotech firms, pharmaceutical companies, and research institutions aiming to bring novel therapeutics to market.
Pomona ricerca
Products & Services
Proteins distribution
Marketing of premium viral proteins of exceptional quality to advance your scientific research.
Custom antibody
Generating, characterizing and engineering monoclonal antibodies sourced from different species.
Custom protein
Customizing your protein design to fit the exact characteristics you require.
Pomona ricerca
News
Avian Influenza virus infections in human
The CDC recently reported four human infections with the highly pathogenic avian influenza (HPAI) A (H5N1) virus
Pediatric Flu deaths in America
On March 8th, a CDC report declared that there have been 103 flu-related pediatric deaths in the 2023-2024 seaso
The 31st annual CROI (Conference on Retroviruses and Opportunistic Infections)
At the beginning of March, the 31st annual CROI, a prominent congress in the field of HIV research, was held in
Pomona ricerca
Partnership
